GlassScriptPhysician profile
Kyung M Han
NPI 1699868224
$15,527.41
in general payments reported to CMS, 2019-2025
41 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,190 · 2020: $2,144 · 2021: $3,012 · 2022: $2,268 · 2023: $1,350 · 2024: $1,848 · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,909 · Education: $4.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,908.85 |
| Education | $4.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,930.15 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $1,574.92 | 2019-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $1,411.90 | 2021-2025 | |
| Novo Nordisk INC | $1,205.45 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Amarin Pharma, INC. | $952.21 | 2019-2022 | |
| Abbvie INC. | $928.05 | 2019-2025 | |
| Lilly USA, LLC | $899.08 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $714.40 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $627.57 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $513.93 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $384.23 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $337.32 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Ironwood Pharmaceuticals, INC | $328.24 | 2020-2025 | Linzess |
| Scilex Pharmaceuticals INC. | $314.69 | 2019-2023 | Ztlido |
| Sunovion Pharmaceuticals INC. | $284.03 | 2021-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $277.75 | 2023-2025 | Gemtesa |
| Aimmune Therapeutics, INC. | $254.39 | 2024-2025 | Zenpep |
| Eisai INC. | $244.49 | 2020-2021 | |
| Radius Health, INC. | $230.04 | 2019-2021 | |
| Esperion Therapeutics, INC. | $226.03 | 2021-2025 | Nexletol |
| Ardelyx, INC. | $222.32 | 2024-2025 | Ibsrela |
| Astellas Pharma US INC | $190.21 | 2019-2022 | |
| Allergan, INC. | $185.91 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $183.69 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $178.31 | 2021-2025 | Eliquis |
| Vivus LLC | $170.12 | 2021-2025 | Pancreaze |
| Novartis Pharmaceuticals Corporation | $125.47 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $113.23 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $96.35 | 2023-2025 | Rexulti |
| Almatica Pharma LLC | $63.42 | 2022-2024 | Loreev Xr |
| Gilead Sciences, INC. | $58.90 | 2019-2022 | |
| Lundbeck LLC | $52.27 | 2024 | Rexulti |
| Arbor Pharmaceuticals, INC. | $45.82 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $39.97 | 2021 | |
| Smith+Nephew, INC. | $39.94 | 2020-2025 | Collagenase Santyl |
| Xeris Pharmaceuticals, INC. | $24.00 | 2020 | |
| Exact Sciences Corporation | $23.52 | 2024 | Cologuard Collection Kit |
| Corium, LLC | $20.68 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.65 | 2019 | |
| Ibsa Pharma INC. | $17.78 | 2021 | |
| Dexcom, INC. | $15.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyung Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.